Breast cancer is a common disease. Approximately 1 in 8 American women and 1 in 1,000 American men will develop invasive breast disease during their lifetimes. Although the incidence of breast cancer has decreased since 2000, more than 340,000 new cases of breast cancer are expected to be diagnosed in 2022, including over 290,000 cases of invasive breast cancer and more than 51,000 cases of noninvasive “in situ” tumors.
Improvements in detection and treatment have led to higher survival rates, but breast cancer is still expected to account for nearly 44,000 deaths in 2022 in the United States.1 In situ tumors — that is, those still confined to the breast ducts or lobules — are associated with lower mortality risk than those that progress into other parts of the breast tissue, and some types of invasive breast cancer are more aggressive than others.
Breast cancer is an active area of study for Kaiser Permanente Research. Scientists across the organization have used our rich, comprehensive, longitudinal data to advance knowledge in the areas of understanding risk, improving patient outcomes, and translating research findings into policy and practice. We have published 630 articles related to breast cancer since 2007.2 Together, these articles have been cited over 25,000 times.
These articles are the product of observational studies, randomized controlled trials, meta-analyses, and other studies led by Kaiser Permanente scientists. Our unique environment — a fully integrated care and coverage model in which our research scientists, clinicians, medical groups, and health plan leaders collaborate — lets us contribute important knowledge about breast cancer and many other research topics.